CN105287394A - Propranolole hydrochloride sustained-release pellets and preparation method thereof - Google Patents
Propranolole hydrochloride sustained-release pellets and preparation method thereof Download PDFInfo
- Publication number
- CN105287394A CN105287394A CN201510798768.2A CN201510798768A CN105287394A CN 105287394 A CN105287394 A CN 105287394A CN 201510798768 A CN201510798768 A CN 201510798768A CN 105287394 A CN105287394 A CN 105287394A
- Authority
- CN
- China
- Prior art keywords
- propranolol hydrochloride
- preparation
- pellets
- pulvis talci
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses propranolole hydrochloride sustained-release pellets and a preparation method thereof. The propranolole hydrochloride sustained-release pellets comprise a coating layer, medicine-containing pellets, Eudragit NE-30D, powdered steatile, sodium dodecyl sulfate or polyethylene glycol; propranolole hydrochloride, blank pellets, a filler, a lubricant and an adhesive. The method employs a novel sustained release preparation and a pellets preparation, slow release means delay of drug release rate of the medicine in a dosage form, absorption rate of medicine in the body can be reduced, more stable treatment effect can be realized; pellets can increase the distribution area of the medicine on the surface of the gastrointestinal tract, irritation is reduced, bioavailability is increased, influence due to stomach evacuation factor is not generated, medicine can be uniformly absorbed in the body, individual difference is little, and simultaneous application of two advanced technologies enhances the technical advantage of the propranolole hydrochloride sustained-release pellets.
Description
Technical field
The invention belongs to chemical medicine slow releasing preparation field, be specifically related to a kind of propranolol hydrochloride slow-release micro-pill and preparation method thereof.
Background technology
Angina pectoris is coronary insufficiency, cardiac muscle sharply, caused by ischemia and anoxia be the clinical syndrome of main manifestations with ictal chest pain or chest discomfort.Feature is shirtfront paroxysmal, squeezing property pain, can with other symptoms, pain is mainly positioned at breastbone rear portion, pareordia and left upper extremity can be radiated to, work or excitedly often to occur, each outbreak continues 3 ~ 5 minutes, can a few days once, also can one day for several times, have a rest or disappear with after nitrate preparations.Primary disease is more common in male, most more than 40 years old, tired, excited, be satiated with food, catch cold, rainy weather, acute circulatory failure etc. are common inducement.
At present, market is treated in anginal medicine, there is drug release stablizing effect low, large to gastrointestinal irritation, bioavailability is low, packaging, transport, storage inconvenience, and the deficiency such as preparation method is complicated.
Summary of the invention
The object of this invention is to provide and be a kind ofly applicable to chemical medicine slow-release micro-pill of the symptoms such as heart infarction, hypertension, angina pectoris and preparation method thereof.
In order to realize object of the present invention, the present invention is achieved by the following technical solutions: a kind of propranolol hydrochloride slow-release micro-pill, comprises coatings, pastille micropill; Described coatings is wrapped in outside pastille micropill; Described coatings comprises: 35-175mg is strange NE-30D, 5-53mg Pulvis Talci especially; Described pastille micropill comprises: 40mg propranolol hydrochloride, 80mg celphere, 160-210mg filler, 10-50mg lubricant, 5-25mg binding agent.
The sodium lauryl sulphate of trace, Polyethylene Glycol wherein one or both are also comprised in described coatings.
In described coatings, preferred weight proportion is: 132mg is strange NE-30D, 7mg Pulvis Talci especially.
In described pastille micropill, preferred weight proportion is: 40mg propranolol hydrochloride, 80mg celphere, 190mg filler, 30mg lubricant, 10mg binding agent.
Described filler is microcrystalline Cellulose, and lubricant is Pulvis Talci, and binding agent is hypromellose.
Its manufacture method comprises following operation:
Step 1: get the raw materials ready: by above-mentioned quality proportioning, use pulverizer to pulverize propranolol hydrochloride, crosses 100 mesh sieves;
Step 2: mixing: take propranolol hydrochloride according to above-mentioned quality proportioning, microcrystalline Cellulose put into three-dimensional mixer mixing 30 minutes, make fine drug powder, take out for subsequent use;
Step 3: the preparation of binding agent: take appropriate hypromellose by above-mentioned quality proportioning, adds appropriate hot water and is mixed with the binding agent that concentration is 2%, for subsequent use;
Step 4: pill: charging spout fine drug powder being put into centrifugal pellet processing machine, binding agent puts into feed tank, and celphere is put in centrifugal pellet processing machine, opens machine, adjustment parameter, start hydrojet, start for powder, after all having supplied containing medicated powder when ball core has during damp, Pulvis Talci is added in charging spout, continue for powder, after Pulvis Talci has all supplied, discharging; Then use fluid bed dryer to dry, first use cool breeze dry, after epidermis drying, open Hot-blast Heating, inlet temperature is at 50-55 degree Celsius, and use 14,24 mesh sieve after drying, the pastille micropill getting 14-24 order size is for subsequent use;
Step 5: the preparation of coating materials: take especially strange NE-30D, Pulvis Talci, sodium lauryl sulphate, purified water by above-mentioned quality proportioning, first sodium lauryl sulphate is joined in purified water and stir evenly dissolving, add after especially strange NE-30D stirs evenly again, add Pulvis Talci while stirring, stir for subsequent use after 10 minutes;
Step 6: coating: by the pastille micropill of 14-24 order size, put into fluidized-bed coating machine, coating materials is put into feed tank, stir constantly, open machine, adjustment parameter, starts coating, to be coated dose be finished after, start to heat up and keep temperature of charge more than 40 degrees Celsius, dry 30 minutes, cooling, discharging, closing machine;
Step 7: fill: the pastille micropill after above-mentioned coating is used capsule filling machine, medicament pellet is loaded in 0# capsule;
Step 8: plastic-aluminum: above-mentioned capsule is used aluminium-plastic bubble plate packing machine, is packaged into aluminium-plastic panel, packed products.
Beneficial effect of the present invention: of the present invention take propranolol hydrochloride as the slow-release micro-pill of effective ingredient, mainly with being applicable to the symptoms such as heart infarction, hypertension, angina pectoris.The more novel slow releasing preparation adopted and pellet preparations, slow release-refer to by delaying medicine from the rate of releasing drug this dosage form, reduces the absorption rate that medicine enters body, thus plays more stable therapeutic effect; Micropill has medicine and increases at gastrointestinal tract surface distributed area, can reduce zest, improves bioavailability, does not affect by gastric emptying factor simultaneously, and drug absorption in vivo is even, and individual variation is little; Two kinds of advanced technology apply the technical advantage more enhancing this medicine simultaneously.Its preparation method is simple, is applicable to commercial production.
The present invention is through two groups of clinical verifications, and wherein one group is that treatment group uses the present invention, and every day uses once, within 7 days, be a course for the treatment of, another group contrast uses existing Nifedipine controlled-release tablet, every group selection outpatient 120 example, wherein man 65 example, female 55 example, measures 70 years old large age, minimal ages 20 years old, every day uses once, within 7 days, be a course for the treatment of, clinical manifestation hypotension, bradycardia, dizziness, faint, table one is for taking the contrasting data after the course for the treatment of:
Table 1 is taken front and back and is compared (unit: people) two groups of courses for the treatment of
There were significant differences for treatment group and matched group, thus can find out that the present invention's application clinically has significant curative effect.
Process characteristic of the present invention: 1, select raw material science, production technology is advanced, and its product is conveniently deposited and used; 2, product Chinese medicine composition is easily absorbed by the body; 3, raw material sources are extensive, add process line short, the easy processing and manufacturing of product.
Detailed description of the invention:
Embodiment 1
A kind of propranolol hydrochloride slow-release micro-pill, comprises coatings, pastille micropill; Described coatings is wrapped in outside pastille micropill; Described coatings comprises: 35-175mg is strange NE-30D, 5-53mg Pulvis Talci especially; Described pastille micropill comprises: 40mg propranolol hydrochloride, 80mg celphere, 160-210mg filler, 10-50mg lubricant, 5-25mg binding agent.
The sodium lauryl sulphate of trace, Polyethylene Glycol wherein one or both are also comprised in described coatings.
In described coatings, preferred weight proportion is: 132mg is strange NE-30D, 7mg Pulvis Talci especially.
In described pastille micropill, preferred weight proportion is: 40mg propranolol hydrochloride, 80mg celphere, 190mg filler, 30mg lubricant, 10mg binding agent.
Described filler is microcrystalline Cellulose, and lubricant is Pulvis Talci, and binding agent is hypromellose.
Embodiment 2
Its manufacture method comprises following operation:
Step 1: get the raw materials ready: by above-mentioned quality proportioning, use pulverizer to pulverize propranolol hydrochloride, crosses 100 mesh sieves;
Step 2: mixing: take propranolol hydrochloride according to above-mentioned quality proportioning, microcrystalline Cellulose put into three-dimensional mixer mixing 30 minutes, make fine drug powder, take out for subsequent use;
Step 3: the preparation of binding agent: take appropriate hypromellose by above-mentioned quality proportioning, adds appropriate hot water and is mixed with the binding agent that concentration is 2%, for subsequent use;
Step 4: pill: charging spout fine drug powder being put into centrifugal pellet processing machine, binding agent puts into feed tank, and celphere is put into centrifugal pellet processing machine, opens machine, adjustment parameter, start hydrojet, start for powder, after all having spread containing medicated powder when ball core has during damp, Pulvis Talci is added in charging spout, continue for powder, after Pulvis Talci has all spread, discharging; Then use fluid bed dryer to dry, first use cool breeze dry, after epidermis drying, open Hot-blast Heating, inlet temperature is at 50-55 degree Celsius, and use 14,24 mesh sieve after drying, the pastille micropill getting 14-24 order size is for subsequent use;
Step 5: the preparation of coating materials: take especially strange NE-30D, Pulvis Talci, sodium lauryl sulphate, purified water by above-mentioned quality proportioning, first sodium lauryl sulphate is joined in purified water and stir evenly dissolving, add after especially strange NE-30D stirs evenly again, add Pulvis Talci while stirring, stir for subsequent use after 10 minutes;
Step 6: coating: by the pastille micropill of 14-24 order size, put into fluidized-bed coating machine, coating materials is put into feed tank, stir constantly, open machine, adjustment parameter, starts coating, to be coated dose be finished after, start to heat up and keep temperature of charge more than 40 degrees Celsius, dry 30 minutes, cooling, discharging, closing machine;
Step 7: fill: the pastille micropill after above-mentioned coating is used capsule filling machine, medicament pellet is loaded in 0# capsule;
Step 8: plastic-aluminum: above-mentioned capsule is used aluminium-plastic bubble plate packing machine, is packaged into aluminium-plastic panel, packed products.
Embodiment 3
Indication:
1., as secondary prevention, reduce myocardial infarction mortality rate.
2. hypertension (separately or share with other antihypertensive).
3. exertional angina pectoris.
4. control Supraventricular tachyarrhythmia, ventricular arrhythmia, particularly or Folium Digitalis Purpureae relevant with catecholamine causes arrhythmia.The room that can be used for Folium Digitalis Purpureae unsatisfactory curative effect is flutterred, the control of atrial fibrillation Ventricular Rate, also can be used for intractable premature beat, improves the symptom of patient.
5. lower hypertrophic cardiomyopathy efferent tract pressure reduction, alleviate the symptoms such as angina pectoris, cardiopalmus and faintness.
6. coordinate α receptor blocking agent to be used for pheochromocytoma patient and control tachycardia.
7., for controlling the rapid heart rate of hyperthyroidism, also can be used for treating thyroid storm.
Embodiment 4
Drug interaction
1. interact with antihypertensive drug: this product and reserpine share, and can cause postural hypotension, bradycardia, dizziness, faint.Share with oxidase inhibitor, extremely hypotension can be caused.
2. share with Folium Digitalis Purpureae, atrioventricular block can occur and make decreased heart rate, must close observation.
3. and Combined With Calcium Antagonists, particularly intravenous injection verapamil, very vigilant this product to the suppression of cardiac muscle and conducting system.
4. share with epinephrine, phenylephrine or sympathomimetic amine, remarkable hypertension, heart rate can be caused excessively slow, also can occur atrioventricular block.
5. share with isoproterenol or xanthine, the latter's curative effect can be made to weaken.
6. share with haloperidol, hypotension and heart stopping collecting can be caused.
7. share the intestinal absorption that can reduce Propranolol with gel aluminum hydroxide.
8. ethanol can slow down this product absorption rate.
9. share with phenytoin Sodium, phenobarbital and rifampicin and can accelerate this product and remove.
10. share the blood drug level that can increase both with chlorpromazine.
11. share can reduce this product clearance rate with phenazone, theophylline class and lignocaine.
12. share with thyroxine the reduction causing T3 concentration.
13. share can reduce this product hepatic metabolism with cimetidine, delay to eliminate, increase Propranolol blood drug level.
14. can affect blood sugar level, therefore the used time same with antidiabetic drug, the dosage of the latter need be adjusted.
Embodiment 5
Pharmacological toxicology
Pharmacological action
1. Propranolol is non-selective Competitive assays adrenergic alpha-agonists.Block β 1, the beta 2 receptor on heart, antagonism sympathetic activation and catecholamine effect, reduce contractility and the contraction speed of heart, suppress vascular smooth muscle contraction simultaneously, reduce myocardial oxygen consumption, the oxygen relation between supply and demand of ischemic myocardium is restored balance in low-level, can be used for treating angina pectoris.
2. suppress the adrenergic of heartpacer current potential excited, be used for the treatment of arrhythmia.This product, also by maincenter, adrenergic neuron blockade, suppresses the effect such as renin release and heart output reduction, is used for the treatment of hypertension.
3. the effect of competitive antagonism isoproterenol and norepinephrine, blocks beta 2 receptor, reduces plasma renin activity.Bronchospasm can be caused.Suppress insulin secretion, blood glucose is raised, covers Hypoglycemic symptoms, postpone hypoglycemic recovery.
4. have obvious antiplatelet aggregative activity, this is mainly with the membrane stabilizing action of medicine and suppress platelet membrane Ca [sup] 2+ [/sup] to transport relevant.
Toxicological effect
Carcinogenic, mutagenesis and genotoxicity: in 18 months, rat or mice daily 150mg/kg, 18 months by a definite date, without overt toxicity reaction, without the carcinogenesis relevant to medicine.Reproduction experiment has no the reproductive performance relevant with Propranolol effect and damages.When give with animal 10 doubly to people's dosage time, display this product have fetal toxicity.
Embodiment 6
Pharmacokinetics
The oral rear gastrointestinal absorption of this product is comparatively complete, widely at intrahepatic metabolism, and bioavailability about 30%.Within after taking medicine 1 ~ 1.5 hour, reach peak plasma concentrations, eliminating the half-life is 2 ~ 3 hours, plasma protein binding rate 90 ~ 95%.There is notable difference, apparent volume of distribution 3.9-6.0L/kg in individual blood drug level.Through renal excretion, be mainly metabolite, fraction ([1%) be original shape medicine.Can not discharge through dialysis.
Claims (6)
1. a propranolol hydrochloride slow-release micro-pill, comprises coatings, pastille micropill; It is characterized in that: described coatings is wrapped in outside pastille micropill; Described coatings comprises: 35-175mg is strange NE-30D, 5-53mg Pulvis Talci especially; Described pastille micropill comprises: 40mg propranolol hydrochloride, 80mg celphere, 160-210mg filler, 10-50mg lubricant, 5-25mg binding agent.
2. a kind of propranolol hydrochloride slow-release micro-pill according to claim 1, is characterized in that: also comprise the sodium lauryl sulphate of trace, Polyethylene Glycol wherein one or both in described coatings.
3. a kind of propranolol hydrochloride slow-release micro-pill according to claim 1, is characterized in that: in described coatings, preferred weight proportion is: 132mg is strange NE-30D, 7mg Pulvis Talci especially.
4. a kind of propranolol hydrochloride slow-release micro-pill according to claim 1, is characterized in that: in described pastille micropill, preferred weight proportion is: 40mg propranolol hydrochloride, 80mg celphere, 190mg filler, 30mg lubricant, 10mg binding agent.
5., according to a kind of propranolol hydrochloride slow-release micro-pill in claim 1 and 4 described in any one, it is characterized in that: described filler is microcrystalline Cellulose, lubricant is Pulvis Talci, and binding agent is hypromellose.
6. the preparation method of a kind of propranolol hydrochloride slow-release micro-pill according to claim 1, is characterized in that: comprise following operation:
Step 1: get the raw materials ready: by above-mentioned quality proportioning, use pulverizer to pulverize propranolol hydrochloride, crosses 100 mesh sieves;
Step 2: mixing: take propranolol hydrochloride according to above-mentioned quality proportioning, microcrystalline Cellulose put into three-dimensional mixer mixing 30 minutes, make fine drug powder, take out for subsequent use;
Step 3: the preparation of binding agent: take appropriate hypromellose by above-mentioned quality proportioning, adds appropriate hot water and is mixed with the binding agent that concentration is 2%, for subsequent use;
Step 4: pill: charging spout fine drug powder being put into centrifugal pellet processing machine, binding agent puts into feed tank, and celphere is put into centrifugal pellet processing machine, opens machine, adjustment parameter, start hydrojet, start for powder, after all having spread containing medicated powder when ball core has during damp, Pulvis Talci is added in charging spout, continue for powder, after Pulvis Talci has all spread, discharging; Then use fluid bed dryer to dry, first use cool breeze dry, after epidermis drying, open Hot-blast Heating, inlet temperature is at 50-55 degree Celsius, and use 14,24 mesh sieve after drying, the pastille micropill getting 14-24 order size is for subsequent use;
Step 5: the preparation of coating materials: take especially strange NE-30D, Pulvis Talci, sodium lauryl sulphate, purified water by above-mentioned quality proportioning, first sodium lauryl sulphate is joined in purified water and stir evenly dissolving, add after especially strange NE-30D stirs evenly again, limit is stirred and is just added Pulvis Talci, stirs for subsequent use after 10 minutes;
Step 6: coating: by the pastille micropill of 14-24 order size, put into fluidized-bed coating machine, coating materials is put into feed tank, stir constantly, open machine, adjustment parameter, starts coating, to be coated dose be finished after, start to heat up and keep temperature of charge more than 40 degree, dry 30 minutes, cooling, discharging, closing machine;
Step 7: fill: the pastille micropill after above-mentioned coating is used capsule filling machine, medicament pellet is loaded in 0# capsule;
Step 8: plastic-aluminum: above-mentioned capsule is used aluminium-plastic bubble plate packing machine, is packaged into aluminium-plastic panel, packed products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510798768.2A CN105287394A (en) | 2015-11-19 | 2015-11-19 | Propranolole hydrochloride sustained-release pellets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510798768.2A CN105287394A (en) | 2015-11-19 | 2015-11-19 | Propranolole hydrochloride sustained-release pellets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287394A true CN105287394A (en) | 2016-02-03 |
Family
ID=55185693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510798768.2A Pending CN105287394A (en) | 2015-11-19 | 2015-11-19 | Propranolole hydrochloride sustained-release pellets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287394A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816436A (en) * | 2016-03-22 | 2016-08-03 | 广州共禾医药科技有限公司 | Pantoprazole enteric-coated pellets, pantoprazole enteric-coated controlled-release tablets and preparing method thereof |
| CN107080740A (en) * | 2017-04-24 | 2017-08-22 | 江苏亚邦爱普森药业有限公司 | A kind of Pharmaceutical composition for being used to prepare oral slow-releasing preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2003015A (en) * | 1933-03-31 | 1935-05-28 | United Shoe Machinery Corp | Shoe supporting jack |
| WO2003028708A1 (en) * | 2001-10-04 | 2003-04-10 | Eurand Pharmaceuticals Ltd. | Timed, sustained release multi-particulate dosage forms of propranolol |
| CN101190180B (en) * | 2006-11-20 | 2011-03-30 | 北京利龄恒泰药业有限公司 | Metoprolol sustained release medicinal compositions and preparation method thereof |
| CN102247326A (en) * | 2010-05-17 | 2011-11-23 | 天津药物研究院 | Oral chronopharmacologic drug delivery mini-pill preparation of propranolol and its salts |
-
2015
- 2015-11-19 CN CN201510798768.2A patent/CN105287394A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2003015A (en) * | 1933-03-31 | 1935-05-28 | United Shoe Machinery Corp | Shoe supporting jack |
| WO2003028708A1 (en) * | 2001-10-04 | 2003-04-10 | Eurand Pharmaceuticals Ltd. | Timed, sustained release multi-particulate dosage forms of propranolol |
| CN101190180B (en) * | 2006-11-20 | 2011-03-30 | 北京利龄恒泰药业有限公司 | Metoprolol sustained release medicinal compositions and preparation method thereof |
| CN102247326A (en) * | 2010-05-17 | 2011-11-23 | 天津药物研究院 | Oral chronopharmacologic drug delivery mini-pill preparation of propranolol and its salts |
Non-Patent Citations (2)
| Title |
|---|
| 元英进主编: "《现在制药工艺学》", 31 January 2006 * |
| 温博栋主编: "《半固体及其他制剂技术》", 31 January 2009 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816436A (en) * | 2016-03-22 | 2016-08-03 | 广州共禾医药科技有限公司 | Pantoprazole enteric-coated pellets, pantoprazole enteric-coated controlled-release tablets and preparing method thereof |
| CN107080740A (en) * | 2017-04-24 | 2017-08-22 | 江苏亚邦爱普森药业有限公司 | A kind of Pharmaceutical composition for being used to prepare oral slow-releasing preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL200957B1 (en) | Celecoxib compositions and the use thereof | |
| CN103083319B (en) | Preparation process of compound valsartan amlodipine solid preparation | |
| CN106074445B (en) | The purposes of the drug of illness is eliminated or is reduced in coated drugs orbicule and its preparation | |
| CN104473905A (en) | Trimetazidine hydrochloride sustained-release capsule and preparation method thereof | |
| CN105287394A (en) | Propranolole hydrochloride sustained-release pellets and preparation method thereof | |
| CN103285017A (en) | Compound isosorbide mononitrate aspirin sustained-release capsule preparation and preparation method | |
| CN101990427A (en) | Combination of mitiglinide and metformin and process for preparing same | |
| CN102247366B (en) | Medicinal compositionslow-releaseformulation containing Enalapril and Felodipine | |
| CN104434847A (en) | Choline fenofibric acid sustained release pellets and preparation method thereof | |
| CN101524355B (en) | Compound preparation of antituberculosis medicaments, and preparation method thereof | |
| CN105832731B (en) | It is a kind of to treat medicine of hypertension and preparation method thereof | |
| TWI608849B (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
| CN111202731A (en) | Combined application, medicinal composition and application thereof | |
| CN107018650A (en) | Solid composite medicament comprising Amlodipine and Losartan | |
| WO2018211336A2 (en) | Solid dosage form containing sorafenib tosylate | |
| CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
| CN100455288C (en) | Formula of Reynoldazine hydrochloride prepn. | |
| CN104352470A (en) | Diltiazem hydrochloride sustained release tablets and preparation method thereof | |
| CN1329035C (en) | Method for preparing medicine composition contg. aspirin | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
| CN101406466B (en) | Cinnamic acid transdermal patch and preparation technique thereof | |
| CN105362233A (en) | Sustained-release captopril micro-pill and method for preparing same | |
| CN105287395A (en) | Tamsulosin hydrochloride sustained-release pellets and preparation method thereof | |
| CN105663049A (en) | Apixaban sustained-release pellet and preparation method thereof | |
| CN105663048A (en) | Ranolazine sustained release pellet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |